

Shaping the Future of Personalized Therapy in Ovarian Cancer: A Focus on *BRCA* Biomarkers

Sunday, 28 September 2014 | 18.00-19.45
Salamanca Auditorium

Chair

Ignace Vergote, MD, PhD
University Hospital Gasthuisberg
Leuven, Belgium

Faculty

Judith Balmaña, MD, PhD
Vall d'Hebron University Hospital
Barcelona, Spain

Susana Banerjee, MBBS, MA, MRCP, PhD
Royal Marsden Hospital
London, United Kingdom



This activity is provided
by prIME Oncology.

Agenda

- 18.00 Welcome and introduction
Ignace Vergote, MD, PhD
- 18.05 Treatment of advanced ovarian cancer:
Guideline recommendations and unmet needs
Ignace Vergote, MD, PhD
- 18.25 Audience questions and panel discussion
- 18.35 Testing for *BRCA* gene mutations:
Why, when, and for whom?
Judith Balmaña, MD, PhD
- 18.55 Audience questions and panel discussion
- 19.05 *BRCA*-associated ovarian cancer:
How to personalize first-line and subsequent
therapies?
Susana Banerjee, MBBS, MA, MRCP, PhD
- 19.25 Audience questions and panel discussion
- 19.35 Concluding remarks
Ignace Vergote, MD, PhD
- 19.45 Adjourn

AstraZeneca 

This educational activity
is supported by AstraZeneca.